Association of Difference Between eGFR From Cystatin C and Creatinine and Serum GDF‐15 With Adverse Outcomes in Diabetes Mellitus
Journal of Cachexia, Sarcopenia and Muscle · 2025-08 · 16 (4)
DOI: 10.1002/jcsm.70011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, online erschienen am 23.07.2025. Verfasst von Tomohito Gohda und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Growth Differentiation Factor 15, Cystatin C, Creatinine, Glomerular Filtration Rate. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Protein catabolism and chronic inflammation drive sarcopenia and frailty in individuals with diabetes mellitus and chronic kidney disease (CKD). The difference between estimated glomerular filtration rates derived from cystatin C and creatinine (eGFRcys and eGFRcr, respectively), termed eGFRdiff, along with growth differentiation factor‐15 (GDF‐15) levels, have emerged as markers of metabolic and inflammatory dysregulation. Lower eGFRdiff and elevated GDF‐15 levels are associated with sarcopenia, frailty, CKD progression and mortality. However, their interplay and respective impacts on CKD progression and mortality remain unclear.
Methods
A total of 638 Japanese individuals with diabetes mellitus were stratified into tertiles based on eGFRdiff. Serum GDF‐15 levels were measured using enzyme‐linked immunosorbent assays. The relationships between eGFRdiff and GDF‐15 were assessed using Spearman's correlation coefficients. Multivariate ordered logistic regression was used to evaluate the association between eGFRdiff and GDF‐15 tertiles, with GDF‐15 as the dependent variable and eGFRdiff as the independent variable, adjusting for covariates including age, sex, urinary albumin‐to‐creatinine ratio (UACR) and eGFRcr or eGFRcys. Cox proportional hazards models with restricted cubic splines were used to examine associations between eGFRdiff and GDF‐15 (independent variables) with CKD progression (≥ 30% decline in eGFRcr from baseline) and mortality (dependent variables). These models were adjusted for age, sex, glycated haemoglobin, UACR and eGFRcr.
Results
The median age was 65 years (interquartile range: 58–73), and 53.9% of participants were male. Over median follow‐up periods of 5.3 years for CKD progression and 5.4 years for mortality, 75 participants (11.8%) experienced CKD progression and 44 (6.9%) died. GDF‐15 levels inversely correlated with eGFRdiff ( r = −0.35, p < 0.001). Higher eGFRdiff values were associated with lower odds of being in a higher GDF‐15 tertile (odds ratio 0.86; 95% confidence interval [CI]: 0.76–0.97; p = 0.01). Both lower eGFRdiff and higher GDF‐15 levels were independently associated with adverse outcomes: CKD progression (GDF‐15, hazard ratio [HR] 1.36, 95% CI: 1.02–1.81, p < 0.05; eGFRdiff, HR 0.67, 95% CI: 0.58–0.78, p < 0.0001) and mortality (GDF‐15, HR 2.35, 95% CI: 1.63–3.41, p < 0.0001; eGFRdiff: 0.80, 95% CI: 0.65–0.99, p < 0.05).
Conclusions
Both eGFRdiff and GDF‐15 were independently associated with adverse outcomes in individuals with diabetes mellitus. GDF‐15 showed a stronger association with mortality, whereas eGFRdiff was more strongly linked to CKD progression. These findings underscore the potential utility of these markers in risk stratification for diabetes‐related complications and may guide individualized interventions in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan.
- Department of Endocrinology and Metabolism, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, Japan.
- Institute for Clinical Research, NHO Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.
- Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.
- Department of Cellular Physiology and Signal Transduction, Sapporo Medical University School of Medicine, Sapporo, Japan.
- Department of Endocrinology and Diabetology, NHO Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.
ORCID-Profile: Tomohito Gohda
Zitieren
APA
Gohda, T., Kamei, N., Tanaka, M., Furuhashi, M., Sato, T., Kubota, M., Sanuki, M., Koshida, T., Hagiwara, S., Suzuki, Y., & Murakoshi, M. (2025). Association of Difference Between eGFR From Cystatin C and Creatinine and Serum GDF‐15 With Adverse Outcomes in Diabetes Mellitus. Journal of Cachexia, Sarcopenia and Muscle, 16(4). https://doi.org/10.1002/jcsm.70011
Vancouver
Gohda T, Kamei N, Tanaka M, Furuhashi M, Sato T, Kubota M, et al. Association of Difference Between eGFR From Cystatin C and Creatinine and Serum GDF‐15 With Adverse Outcomes in Diabetes Mellitus. Journal of Cachexia, Sarcopenia and Muscle. 2025;16(4). doi:10.1002/jcsm.70011
BibTeX
@article{Gohda2025,
author = {Gohda, Tomohito and Kamei, Nozomu and Tanaka, Marenao and Furuhashi, Masato and Sato, Tatsuya and Kubota, Mitsunobu and Sanuki, Michiyoshi and Koshida, Takeo and Hagiwara, Shinji and Suzuki, Yusuke and Murakoshi, Maki},
title = {Association of Difference Between eGFR From Cystatin C and Creatinine and Serum GDF‐15 With Adverse Outcomes in Diabetes Mellitus},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2025},
volume = {16},
number = {4},
doi = {10.1002/jcsm.70011}
}
EUVIMED